Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

537
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
537
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

301
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
301
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

577
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
577
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.3K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.3K
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

1.2K
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
1.2K
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

835
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
835

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Improvement of Heart Failure Discrimination by the Integration of the Left Ventricle Global Longitudinal Strain.

Clinics and practice·2026
Same author

Estimating the Clinical, Quality-of-Life and Economic Impact of Optimized Management of Type 2 Diabetes Patients in Spain.

Journal of clinical medicine·2026
Same author

Meta-analysis and Meta-regression for Uncertain Areas and the Estimation of Possible Benefit of Future Therapies.

European cardiology·2025
Same author

Beta-Blockers after Myocardial Infarction without Reduced Ejection Fraction.

The New England journal of medicine·2025
Same author

Identifying Dimensions and Items for a Questionnaire to Assess Medication Adherence in Men and Women with Ischemic Heart Disease: Insights from the GENADHECAR Study.

Patient preference and adherence·2025
Same author

Differential effect of triglycerides on the prognosis of patients with a first versus recurrent acute coronary syndrome.

European journal of clinical investigation·2025

Related Experiment Video

Updated: Jan 10, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.7K

Reclassification of Low or Intermediate Cardiovascular Risk by Determining Lipoprotein(a) Levels.

Alberto Cordero1,2,3, José Ma Salinas4, María Amparo Quintanilla1

  • 1Cardiology Department, Hospital Universitario de San Juan, 03550 Alicante, Spain.

Biomedicines
|November 27, 2025
PubMed
Summary
This summary is machine-generated.

Lipoprotein(a) [Lp(a)] testing identifies significant cardiovascular risk in individuals initially assessed as low or moderate risk. This testing also determines eligibility for statin therapy, improving cardiovascular disease prevention strategies.

Keywords:
Lipoprotein(a)reclassificationrisk

More Related Videos

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.0K
Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

12.3K

Related Experiment Videos

Last Updated: Jan 10, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.7K
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.0K
Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

12.3K

Area of Science:

  • Cardiology
  • Preventive Medicine
  • Clinical Biochemistry

Background:

  • Lipoprotein(a) [Lp(a)] is a recognized independent risk factor for cardiovascular disease.
  • Lifetime determination of Lp(a) levels is recommended for comprehensive cardiovascular risk assessment.
  • Current risk stratification models may not fully capture Lp(a)]-associated risk.

Purpose of the Study:

  • To evaluate the impact of Lipoprotein(a) [Lp(a)] testing on cardiovascular risk reclassification.
  • To assess the eligibility for statin therapy based on Lp(a) levels in a low-to-moderate risk cohort.
  • To integrate Lp(a) measurements into existing cardiovascular risk prediction tools like SCORE2.

Main Methods:

  • Subjects with low or moderate cardiovascular risk (SCORE2) underwent Lp(a) determination.
  • Individuals with Lp(a) > 50 mg/dL were categorized as higher risk.
  • Statin eligibility was assessed based on established treatment targets and Lp(a) results.

Main Results:

  • 22.1% of the cohort exhibited Lp(a) levels > 50 mg/dL, indicating higher cardiovascular risk.
  • Incorporating Lp(a) reclassified 22.6% from low to moderate risk and 77.4% from moderate to high risk.
  • 61.4% of subjects became eligible for statin treatment following Lp(a) testing.

Conclusions:

  • Lipoprotein(a) [Lp(a)] testing significantly reclassifies cardiovascular risk in a substantial proportion of individuals initially deemed low or moderate risk.
  • Routine Lp(a) measurement identifies a high percentage of patients eligible for statin therapy, enhancing preventive cardiology strategies.
  • Integrating Lp(a) into risk scores like SCORE2 improves the accuracy of cardiovascular risk stratification and guides treatment decisions.